Eton Pharmaceuticals (ETON) Price & Analysis

Compare

487 Followers

ETON Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.25 - $21.48

Previous CloseN/A

Volume127.06K

Average Volume (3M)564.10K

Market Cap

$388.59M

Enterprise Value$369.64M

Total Cash (Recent Filing)$17.42M

Total Debt (Recent Filing)$87.00K

Price to Earnings (P/E)―

Beta1.00

Next Earnings

Aug 07, 2025

EPS Estimate

0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding26,817,535

10 Day Avg. Volume411,725

30 Day Avg. Volume564,104

Financial Highlights & Ratios

PEG Ratio4.20

Price to Book (P/B)15.74

Price to Sales (P/S)0.00

P/FCF Ratio-524.44

Enterprise Value/Market Cap0.95

Enterprise Value/Revenue2.41

Enterprise Value/Gross Profit13.08

Enterprise Value/Ebitda-30.30

Forecast

1Y Price Target

$30.50

Price Target Upside110.49% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Eton Pharmaceuticals News

PremiumThe Fly

Eton Pharmaceuticals’ NDA for ET-600 solution accepted by FDA

8d ago

ETON

PremiumThe Fly

Eton Pharmaceuticals management to meet with B. Riley

9d ago

ETON

PremiumThe Fly

Eton Pharmaceuticals to be added to Russell 2000, Russell 3000 Indexes

19d ago

ETON

PremiumRatings

Eton Pharmaceuticals’ ET-600 Launch and Strategic Expansion Drive Buy Rating

7d ago

ETON

PremiumCompany Announcements

Eton Pharmaceuticals’ New Drug Application Accepted by FDA

8d ago

ETON

PremiumCompany Announcements

Eton Pharmaceuticals Joins Russell 3000 and 2000 Indexes

19d ago

ETON

PremiumCompany Announcements

Eton Pharmaceuticals Holds Annual Stockholders Meeting

1M ago

ETON

PremiumThe Fly

Eton Pharmaceuticals price target raised to $35 from $33 at H.C. Wainwright

2M ago

ETON

See All ETON News

See All News >

Bulls Say, Bears Say

Bulls Say

Product LaunchET-600, if approved, will be the only FDA-approved oral liquid formulation of desmopressin, potentially capturing a unique market segment.

Revenue GrowthMultiple high-margin products like Increlex and ET-400 are expected to become key contributors to total revenue growth, enhancing the company's financial performance.

Bears Say

Intellectual PropertyPotential legal and intellectual property challenges could hinder the company's ability to capitalize fully on its new and existing products.

Risk FactorsRisks to the Buy rating include clinical, commercial, collaboration, dilution, legal and intellectual property, and competition, posing challenges to stock performance.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

24.52% Insiders

5.60% Mutual Funds

33.69% Other Institutional Investors

31.97% Public Companies and Individual Investors

Detailed Ownership Overview >

ETON FAQ

What was Eton Pharmaceuticals’s price range in the past 12 months?

Eton Pharmaceuticals lowest stock price was $3.25 and its highest was $21.48 in the past 12 months.

What is Eton Pharmaceuticals’s market cap?

Eton Pharmaceuticals’s market cap is $388.59M.

When is Eton Pharmaceuticals’s upcoming earnings report date?

Eton Pharmaceuticals’s upcoming earnings report date is Aug 07, 2025 which is in 22 days.

How were Eton Pharmaceuticals’s earnings last quarter?

Eton Pharmaceuticals released its earnings results on May 13, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of $0.053 by -$0.113.

Is Eton Pharmaceuticals overvalued?

According to Wall Street analysts Eton Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Eton Pharmaceuticals pay dividends?

Eton Pharmaceuticals does not currently pay dividends.

What is Eton Pharmaceuticals’s EPS estimate?

Eton Pharmaceuticals’s EPS estimate is 0.01.

How many shares outstanding does Eton Pharmaceuticals have?

Eton Pharmaceuticals has 26,817,535 shares outstanding.

What happened to Eton Pharmaceuticals’s price movement after its last earnings report?

Eton Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, missing expectations of $0.053. Following the earnings report the stock price went up 0.293%.

Which hedge fund is a major shareholder of Eton Pharmaceuticals?

Currently, no hedge funds are holding shares in ETON

Eton Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-22.95%

Trailing 12-Months

Asset Growth

172.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare and orphan diseases. The company operates primarily in the healthcare sector, delivering high-value therapeutic solutions that target unmet medical needs. Eton Pharmaceuticals' core products include a portfolio of FDA-approved and development-stage drugs designed to address conditions within neurology, endocrinology, and other niche medical fields.

ETON Earnings Call

Q1 2025

0:00 / 0:00

ETON Stock 12 Month Forecast

Average Price Target

$30.50

▲(110.49%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","19":"$19","36":"$36","10.5":"$10.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,10.5,19,27.5,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.01,15.624615384615385,17.23923076923077,18.853846153846156,20.46846153846154,22.083076923076923,23.697692307692307,25.31230769230769,26.926923076923078,28.541538461538465,30.15615384615385,31.770769230769233,33.385384615384616,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.01,15.278461538461539,16.546923076923076,17.815384615384616,19.083846153846153,20.352307692307694,21.62076923076923,22.88923076923077,24.157692307692308,25.426153846153845,26.694615384615386,27.963076923076926,29.231538461538463,{"y":30.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.01,14.932307692307692,15.854615384615384,16.776923076923076,17.69923076923077,18.62153846153846,19.543846153846154,20.466153846153844,21.388461538461538,22.310769230769232,23.233076923076922,24.155384615384612,25.07769230769231,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.63,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.91,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >